Literature DB >> 12492473

Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide.

Eduardo Latorre1, M Pilar Collado, Inmaculada Fernández, M Dolores Aragonés, R Edgardo Catalán.   

Abstract

Ceramide is a lipid second messenger that acts on multiple-target enzymes, some of which are involved in other signal-transduction systems. We have previously demonstrated that endogenous ceramide modifies the metabolism of brain ethanolamine plasmalogens. The mechanism involved was studied. On the basis of measurements of breakdown products, specific inhibitor effects, and previous findings, we suggest that a plasmalogen-selective phospholipase A2 is the ceramide target. Arachidonate-rich pools of the diacylphosphatidylethanolamine subclass were also affected by ceramide, but the most affected were plasmalogens. Concomitantly with production of free arachidonate, increased 1-O-arachidonoyl ceramide formation was observed. Quinacrine (phospholipase A2 inhibitor) and 1-O-octadecyl-2-O-methyl-rac-glycerol-3-phosphocholine (CoA-independent transacylase inhibitor) prevented all of these ceramide-elicited effects. Therefore, phospholipase and transacylase activities are tightly coupled. Okadaic acid (phosphatase 2A inhibitor) and PD 98059 (mitogen-activated protein kinase inhibitor) modified basal levels of ceramide and sphingomyelinase-induced accumulation of ceramide, respectively. Therefore, they provided no evidence to determine whether there is a sensitive enzyme downstream of ceramide. The evidence shows that there are serine-dependent and thiol-dependent enzymes downstream of ceramide generation. Furthermore, experiments with Ac-DEVD-CMK (caspase-3 specific inhibitor) have led us to conclude that caspase-3 is downstream of ceramide in activating the brain plasmalogen-selective phospholipase A2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12492473     DOI: 10.1046/j.1432-1033.2003.03356.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

Review 1.  Studies on plasmalogen-selective phospholipase A2 in brain.

Authors:  Akhlaq A Farooqui
Journal:  Mol Neurobiol       Date:  2010-01-06       Impact factor: 5.590

2.  High activity of acid sphingomyelinase in major depression.

Authors:  J Kornhuber; A Medlin; S Bleich; V Jendrossek; A W Henkel; J Wiltfang; E Gulbins
Journal:  J Neural Transm (Vienna)       Date:  2005-11       Impact factor: 3.575

3.  Reduction of Ether-Type Glycerophospholipids, Plasmalogens, by NF-κB Signal Leading to Microglial Activation.

Authors:  Md Shamim Hossain; Yuichi Abe; Fatma Ali; Mohammed Youssef; Masanori Honsho; Yukio Fujiki; Toshihiko Katafuchi
Journal:  J Neurosci       Date:  2017-03-14       Impact factor: 6.167

Review 4.  Oxidative Stress in Patients with X-Linked Adrenoleukodystrophy.

Authors:  Marion Deon; Desirèe P Marchetti; Bruna Donida; Moacir Wajner; Carmen Vargas
Journal:  Cell Mol Neurobiol       Date:  2015-07-14       Impact factor: 5.046

5.  Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin.

Authors:  Mushfiquddin Khan; Jaspreet Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2008-06-07       Impact factor: 5.372

6.  Lipidomics of Alzheimer's disease: current status.

Authors:  Paul L Wood
Journal:  Alzheimers Res Ther       Date:  2012-02-01       Impact factor: 6.982

7.  Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice.

Authors:  Masataka Ifuku; Toshihiko Katafuchi; Shiro Mawatari; Mami Noda; Kiyotaka Miake; Masaaki Sugiyama; Takehiko Fujino
Journal:  J Neuroinflammation       Date:  2012-08-13       Impact factor: 8.322

8.  Lipids and fatty acids of nudibranch mollusks: potential sources of bioactive compounds.

Authors:  Natalia V Zhukova
Journal:  Mar Drugs       Date:  2014-08-19       Impact factor: 5.118

Review 9.  Plasmalogens, platelet-activating factor and beyond - Ether lipids in signaling and neurodegeneration.

Authors:  Fabian Dorninger; Sonja Forss-Petter; Isabella Wimmer; Johannes Berger
Journal:  Neurobiol Dis       Date:  2020-08-28       Impact factor: 5.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.